

ASX ANNOUNCEMENT

12 FEBRUARY 2026

CHM CDH17 ADVANCES TO DOSE LEVEL 3

- **CHM CDH17 advances to Dose Level 3 of 450 million CDH17 CART+ cells**
- **Dose Levels 1 and 2 were completed with no safety or off target effects observed**
- **Patients treated at Dose Level 2 continue to experience disease control with evidence of anti-tumour activity**
- **CHM CDH17 CART+ cells have been detected in the blood for more than 12 months, indicating exceptional persistence**

Sydney, Australia, 12 February 2026: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), is pleased to announce that the CHM CDH17 clinical trial has advanced to Dose Level 3, following no safety concerns or off target effects observed at Dose Level 1 and Dose Level 2.

Dose Level 1 (50 million) and Dose Level 2 (150 million) CHM CDH17 CART+ cells in clinical trial subjects provided early signs of activity and a compelling safety profile. Four patients have been treated in Dose Level 1, and five in Dose Level 2, with one additional patient pending. Eleven successful manufacturing runs have now been completed.

With this foundation, the Company has now escalated to Dose Level 3 where 450 million CHM CDH17 CART+ cells have been administered to the first patient in the cohort.

Chimeric is encouraged by these safety findings and early signs of clinical activity with one Colorectal Cancer (CRC) patient experiencing stable disease for 13 months from a single dose at Dose Level 1. Another CRC patient has experienced stable disease that is ongoing at nine months from a single dose at Dose Level 2. Both patients are continuing on study and have not required any other therapies throughout this time. All subjects have demonstrated expansion and persistence of the CHM CDH17 CART+ cells for up to 12 months to date.

The clinical expansion observed, coupled with no evidence of off-tumour effects or gastrointestinal toxicity, significantly de-risks CHM CDH17.

“Given what we’ve seen to date at much lower doses, we are particularly eager to see the response from Dose Level 3 in patients, which will conclude the Phase 1 portion of this study,” said Dr Rebecca McQualter, CEO of Chimeric Therapeutics.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs). CHM



CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumours.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in *Nature Cancer* demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.



Contact

Investors

Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au